Profile data is unavailable for this security.
About the company
Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of small molecules and antibody therapies based on the modulation of cellular protein levels as a treatment approach for cancer, inflammatory conditions and other diseases. It DELigase is an integrated discovery platform, to identify and advance drug candidates targeting E3 ligases. Its drug candidates include NX-2127, NX-5948 and NX-1607. NX-2127 is an orally bioavailable Brutons tyrosine kinase (BTK) degrader that also degrades cereblon neosubstrates IKZF1 (Ikaros) and IKZF3 (Aiolos) for the treatment of relapsed or refractory B-cell malignancies. NX-5948 is an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and potentially autoimmune diseases. NX-1607 is an oral clinical-stage small molecule drug candidate that inhibits Casitas B-lineage lymphoma proto-oncogene-B (CBL-B).
- Revenue in USD (TTM)80.89m
- Net income in USD-144.73m
- Incorporated2009
- Employees284.00
- LocationNurix Therapeutics Inc1700 Owens St Ste 205SAN FRANCISCO 94158-0006United StatesUSA
- Phone+1 (415) 660-5320
- Fax+1 (415) 525-4200
- Websitehttps://www.nurixtx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Silence Therapeutics plc | 33.76m | -44.67m | 933.20m | 115.00 | -- | 6.69 | -- | 27.64 | -0.3925 | -0.3925 | 0.2866 | 1.14 | 0.1829 | -- | 5.37 | 293,575.70 | -24.20 | -43.60 | -27.21 | -54.91 | 69.72 | -- | -132.31 | -287.30 | -- | -- | 0.0022 | -- | 44.99 | -- | -6.86 | -- | 156.10 | -- |
Disc Medicine Inc | 0.00 | -80.60m | 938.18m | 74.00 | -- | 2.77 | -- | -- | -3.37 | -3.37 | 0.00 | 13.69 | 0.00 | -- | -- | 0.00 | -26.96 | -- | -28.13 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -63.22 | -- | -- | -- |
Enliven Therapeutics Inc | 0.00 | -79.60m | 961.43m | 46.00 | -- | 3.01 | -- | -- | -1.93 | -1.93 | 0.00 | 6.79 | 0.00 | -- | -- | 0.00 | -24.66 | -42.26 | -26.11 | -46.62 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4,910.75 | -- | -- | -- |
Relay Therapeutics Inc | 35.33m | -329.12m | 974.32m | 309.00 | -- | 1.30 | -- | 27.58 | -2.64 | -2.64 | 0.2841 | 5.64 | 0.0376 | -- | -- | 109,371.50 | -35.03 | -28.55 | -37.16 | -29.54 | -- | -- | -931.64 | -998.20 | -- | -- | 0.00 | -- | 1,749.82 | -- | -17.72 | -- | 19.59 | -- |
OPKO Health Inc | 799.60m | -252.43m | 982.76m | 3.93k | -- | 0.7845 | -- | 1.23 | -0.3427 | -0.3427 | 1.08 | 1.80 | 0.3859 | 7.53 | 6.87 | 203,461.30 | -12.18 | -7.14 | -13.58 | -8.14 | 32.63 | 34.42 | -31.56 | -13.83 | 1.58 | -4.96 | 0.2217 | -- | -14.01 | -2.70 | 42.49 | -- | -10.19 | -- |
Cassava Sciences Inc | 0.00 | -47.90m | 992.15m | 29.00 | -- | 11.38 | -- | -- | -1.17 | -1.17 | 0.00 | 1.82 | 0.00 | -- | -- | 0.00 | -25.63 | -30.74 | -33.88 | -32.12 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.50 | -- | -- | -- |
Tyra Biosciences Inc | 0.00 | -75.45m | 999.83m | 49.00 | -- | 2.56 | -- | -- | -1.68 | -1.68 | 0.00 | 7.43 | 0.00 | -- | -- | 0.00 | -22.87 | -- | -23.31 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.96 | -- | -- | -- |
Nurix Therapeutics Inc | 80.89m | -144.73m | 999.86m | 284.00 | -- | 4.91 | -- | 12.36 | -2.65 | -2.65 | 1.48 | 3.43 | 0.2369 | -- | -- | 284,813.40 | -42.39 | -33.01 | -54.58 | -39.66 | -- | -- | -178.93 | -260.65 | -- | -- | 0.00 | -- | 99.31 | 15.50 | 20.19 | -- | 39.42 | -- |
Innoviva Inc | 311.59m | 181.39m | 1.00bn | 112.00 | 7.32 | 1.43 | 4.56 | 3.21 | 2.19 | 2.19 | 3.88 | 11.21 | 0.2599 | 0.9935 | 4.10 | 2,782,054.00 | 15.13 | 26.24 | 15.57 | 28.53 | 86.12 | -- | 58.21 | 76.84 | 9.17 | -- | 0.3883 | -- | -6.30 | 3.53 | -15.99 | -14.57 | -- | -- |
Ironwood Pharmaceuticals, Inc. | 413.55m | -1.05bn | 1.02bn | 267.00 | -- | -- | -- | 2.46 | -6.79 | -6.79 | 2.52 | -2.08 | 0.5189 | -- | 4.41 | 1,548,880.00 | -135.68 | -4.54 | -164.13 | -5.20 | -- | -- | -261.50 | -7.81 | -- | 8.27 | 1.96 | -- | 7.83 | 5.02 | -672.50 | -- | 160.10 | -- |
Collegium Pharmaceutical Inc | 566.92m | 93.29m | 1.04bn | 197.00 | 15.40 | 4.67 | 4.33 | 1.83 | 2.06 | 2.06 | 12.06 | 6.79 | 0.4869 | 7.07 | 3.20 | 2,877,782.00 | 8.01 | 2.79 | 12.70 | 4.80 | 60.01 | 50.88 | 16.46 | 5.16 | 1.14 | 3.10 | 0.7372 | 0.00 | 22.17 | 15.11 | 292.60 | -- | -54.77 | -- |
Liquidia Corp | 15.97m | -107.69m | 1.05bn | 136.00 | -- | 12.21 | -- | 66.06 | -1.57 | -1.57 | 0.2359 | 1.13 | 0.098 | -- | 4.77 | 117,404.40 | -66.06 | -55.02 | -72.44 | -62.69 | 76.82 | 82.18 | -674.42 | -474.59 | 7.50 | -28.61 | 0.4944 | -- | 9.75 | 45.23 | -91.40 | -- | 66.93 | -- |
Holder | Shares | % Held |
---|---|---|
Redmile Group LLCas of 31 Mar 2024 | 4.48m | 7.56% |
Baker Bros. Advisors LPas of 31 Mar 2024 | 3.88m | 6.55% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 3.85m | 6.49% |
Deep Track Capital LPas of 31 Mar 2024 | 3.00m | 5.05% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 2.73m | 4.60% |
ARK Investment Management LLCas of 31 Mar 2024 | 2.64m | 4.44% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 2.55m | 4.30% |
Morgan Stanley & Co. LLCas of 31 Mar 2024 | 2.36m | 3.97% |
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 2.13m | 3.60% |
DWS Investments (UK) Ltd.as of 31 Mar 2024 | 1.50m | 2.53% |